What is the 13F Pro Quality Score for GUTS?

13F Pro ranks FRACTYL HEALTH, INC. (GUTS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GUTS's current score at https://13fpro.ai/research/GUTS (free sign-up required for the full ranking).

Where does 13F Pro source GUTS data?

All FRACTYL HEALTH, INC. fundamentals and ownership data come directly from SEC EDGAR. FRACTYL HEALTH, INC. files with the SEC under CIK 1572616. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GUTS in?

FRACTYL HEALTH, INC. (GUTS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GUTS research updated on 13F Pro?

GUTS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

FRACTYL HEALTH, INC.(GUTS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1572616 GUTS stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.1M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

GUTS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for FRACTYL HEALTH, INC. (GUTS), a Healthcare sector company. GUTS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), FRACTYL HEALTH, INC. reports net income of $9.2M, free cash flow of $-22.5M. Top institutional holders of GUTS by reported 13-F value include Nantahala Capital Management,, 683 Capital Management,, Pale Fire Capital SE, based on the most recent SEC filings. GUTS trades on the Nasdaq exchange and files with the SEC under CIK 1572616. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GUTS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for FRACTYL HEALTH, INC. directly from SEC EDGAR.

Net Income

Q1 2026

$9.2M

Free Cash Flow

Q1 2026

$-22.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-100.0% YoY

$0.00FY 2025

FY23 $120.0KFY24 $93.0KFY25 $0.00

Net Income

-105.2% YoY

$-141.0MFY 2025

FY23 $-77.1MFY24 $-68.7MFY25 $-141.0M

Operating Income

-3.5% YoY

$-96.8MFY 2025

FY23 $-50.8MFY24 $-93.5MFY25 $-96.8M

EPS (Diluted)

-14.8% YoY

$-1.86FY 2025

FY23 $-45.29FY24 $-1.62FY25 $-1.86

Total Assets

+12.3% YoY

$121.4MFY 2025

FY23 $76.2MFY24 $108.1MFY25 $121.4M

Op. Cash Flow

-37.9% YoY

$-90.3MFY 2025

FY23 $-42.8MFY24 $-65.5MFY25 $-90.3M

Metric	FY 2025	FY 2024	FY 2023
Revenue	$0.00 -100.0%	$93.0K -22.5%	$120.0K
Net Income	$-141.0M -105.2%	$-68.7M +10.9%	$-77.1M
Operating Income	$-96.8M -3.5%	$-93.5M -84.0%	$-50.8M
EPS (Diluted)	$-1.86 -14.8%	$-1.62 +96.4%	$-45.29
Total Assets	$121.4M +12.3%	$108.1M +41.8%	$76.2M
Operating Cash Flow	$-90.3M -37.9%	$-65.5M -53.0%	$-42.8M

AI Insight: GUTS Financial Trends

Fractyl swung to Q1 2026 net income profit of $9M after eight consecutive quarters of losses, but revenue remains absent and operating cash burn persists.

• Net income turned positive at $9M in Q1 2026, reversing losses of $44M in Q4 2025 and $46M in Q3 2025.

• Operating income deficit narrowed to $21M in Q1 2026 from $26M in Q2 2025, showing improving operational efficiency.

• Operating cash outflow remains elevated at $22M in Q1 2026, consistent with prior quarters despite profit inflection.

⚠ Revenue stays at or near zero across all eight quarters — no commercial traction evident despite net income turnaround.

⚠ Equity swung from negative $18M in Q2 2025 and negative $3M in Q3 2025 to positive $9M–$21M; solvency highly fragile.

AI Insight: GUTS Ratio Trends

GUTS swung from severe losses (ROA -92.4% in Q4 2024) to positive returns (ROE 172.5%, ROA 37.1% in Q1 2026), signaling a potential inflection.

• ROA rebounded sharply from -92.4% in Q4 2024 to +37.1% in Q1 2026, indicating profitability recovery.

• ROE turned positive at 172.5% in Q1 2026, reversing from -184.2% loss in Q3 2024.

⚠ Data gaps persist across OpMargin, NPM, ROIC, and D/E—visibility limited on margins, leverage, and true capital efficiency.

⚠ Annualized quarterly metrics are volatile; Q1 2026 rebound may reflect seasonality or one-time items rather than sustained operational improvement.

Get alerted when GUTS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for FRACTYL HEALTH, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GUTS

Nantahala Capital Management, LLC
$6.1M13,364,519 sh
683 Capital Management, LLC
$3.1M6,727,235 sh
Pale Fire Capital SE
$2.7M5,921,045 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.5M5,533,006 sh
Catalio Capital Management, LP
$2.5M5,491,866 sh
General Catalyst Group Management, LLC
$2.2M4,884,193 sh
Deer Management Co. LLC
$2.2M4,770,901 sh
MAVERICK CAPITAL LTD
$1.8M3,974,806 sh
Woodline Partners LP
$1.0M2,241,679 sh
BlackRock, Inc.
$979.6K2,139,837 sh

Fund	Value	Shares
Nantahala Capital Management, LLC	$6.1M	13,364,519
683 Capital Management, LLC	$3.1M	6,727,235
Pale Fire Capital SE	$2.7M	5,921,045
VANGUARD CAPITAL MANAGEMENT LLC	$2.5M	5,533,006
Catalio Capital Management, LP	$2.5M	5,491,866
General Catalyst Group Management, LLC	$2.2M	4,884,193
Deer Management Co. LLC	$2.2M	4,770,901
MAVERICK CAPITAL LTD	$1.8M	3,974,806
Woodline Partners LP	$1.0M	2,241,679
BlackRock, Inc.	$979.6K	2,139,837

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GUTS on your watchlist

Track score changes the day FRACTYL HEALTH, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GUTS a good stock to buy?

13F Pro's AI-powered analysis of FRACTYL HEALTH, INC. (GUTS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GUTS are available on the GUTS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GUTS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GUTS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of FRACTYL HEALTH, INC.'s investment landscape.